Fenoterol
From Wikipedia, the free encyclopedia
|
Fenoterol
|
|
| Systematic (IUPAC) name | |
| (RS)-1-(3,5-Dihydroxyphenyl)- 2-[(RS)-2-(4-hydroxyphenyl)- 1-methylethylamino]ethanol | |
| Identifiers | |
| CAS number | |
| ATC code | R03 G02CA03 |
| PubChem | |
| Chemical data | |
| Formula | C17H21NO4 |
| Mol. mass | 303.35 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Inhaled |
Fenoterol is an asthma medication designed to open up the airways to the lungs. It is classed as a beta agonist.
It was a long-acting beta-agonist widely used in New Zealand in the early 1990s but withdrawn because of its association with an excess number of deaths.
[edit] References
- Beasley R, Pearce N, Crane J, Burgess C. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):325-7.
- Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20, 1992;326(8):501-6.
|
||||||||||||||||||||||||||

